PI Health Sciences announces the acquisition of Archimica S.p.A from Livia Group
April 28, 2023
We are pleased to announce that today PI Health Sciences has acquired Archimica S.p.A (headquarter in Lodi, Italy). PI Health Sciences will provide to Archimica the opportunity to integrate Archimica’s value chain and enhance the security of supplies by using PI’s technological excellence.
New Archimica business portfolio will include CRO solutions, CDMO solutions, and KSM/API solutions. With 75+ years of successful building diverse business, PI Health Sciences will enable Archimica to continue its growth path.
About PI Health Sciences
PI Health Sciences is a wholly owned subsidiary of PI Industry.
PI Industry, incorporated in 1947, listed at stock Mumbai, India, is known as a leader in specialty chemistry serving global innovators. PI Industries’ core values of trust, adaptability, speed and innovation enable them to deliver the highest value to its customers and respect IP of its partners. PI Industries is known for best-in-class manufacturing, quality, and EHS practices. The Company is a strong believer in technology and is focusing on Industry 4.0 standards for its manufacturing plants, with strong focus on innovation.
With strength of over 3,500 employees, the Company currently operates a strong infrastructure set-up consisting of 3 formulation facilities as well as 15 multi-product plants under its 4 manufacturing locations. These state-of-the-art facilities have integrated process development teams with in-house engineering capabilities. The Company maintains a strong research presence through its R&D facility at Udaipur, where it has a dedicated team of over 500+ scientists and chemists. The facility includes advanced research and development labs, kilo plants and pilot plants with NABL certification.
“We are excited about this acquisition as it marks a solid and accelerated beginning of PI’s journey in the pharma space. Our unique ability to build concrete offerings from abstract situations and leverage our capabilities across complex chemistries in the value chain will once again help create a differentiated value proposition for our stakeholders. This acquisition aligns with PI’s approach of working with global innovators and being at the forefront of innovation, science, technology and human ingenuity to create transformative solutions in life sciences with the purpose of reimagining a healthier planet. We are excited to welcome the talented team from Archimica to the PI family. We look forward to deploying all our combined expertise towards unique value delivery for our customers. I compliment PI’s leadership team and external advisors in fructifying this strategic opportunity”, said Mayank Singhal, Vice Chairperson & Managing Director of PI Industries Ltd.
About LIVIA Group
LIVIA Group is an independent industrial holding as well as the private investment enterprise of Prof. Dr. Dr. Peter Löw with funds under management of more than EUR 782m. LIVIA invests in a diverse spectrum of assets, ranging from corporate, agricultural and opportunistic investments to real estate, emerging markets, and fine arts & antiques. More than 250 executed transactions made LIVIA’s management a preferred and trusted partner of international corporations and financial institutions.
LIVIA Corporate Development is specialized in acquiring European corporate spin-offs / carve-outs as well as midsized companies with revenues between EUR 20m and EUR 2bn. The focus is on business transformations and acquisitions of underperforming companies with operational improvement potential as well as add-on acquisitions for existing platform investments to realize synergies.
“Our investment in Archimica SpA has been a great success story for all the stakeholders in the business. The sale of Archimica to the strategic buyer PI Health Sciences is the final piece in our strategy of fully utilize Archimica’s potential”, comments Prof. Dr. Dr. Peter Löw, founder and owner of LIVIA GROUP. “Like Archimica, PI Health Sciences is pursuing an ambitious growth strategy and is in a perfect position to support the company in its future development.”
For more information, visit